Close Menu

Tech Transfer Tidbits


Pfizer and University College London Ink Research, Licensing Pact for Stem Cell-Based Ophthalmologic Rxs

Pfizer's Regenerative Medicine unit has inked a sponsored research and licensing agreement with University College London to develop stem cell-based therapies for ophthalmic conditions, Pfizer said last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.